摘要 |
The disclosure is directed to novel predictive methods and personalized therapies for treating an autoimmune disease (AI) selected from psoriasis, uveitis, rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and multiple sclerosis (MS). Specifically, this disclosure relates to methods of treating a patient having an AI disease by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having uveitis, RA, PsA, AS, psoriasis or MS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab. |